Company presents Letybo, Revolax, Byryzn BR, and Wellage in Taipei
Employees of Hugel’s Taiwan subsidiary posing for a commemorative photo at the ‘AMWC ASIA & TDAC 2026’ venue. (Photo courtesy of Hugel)
Hugel, Inc., a global total medical aesthetics company, announced that it participated in the ‘AMWC ASIA & TDAC 2026’, held from May 2 to 3 at the Taipei International Convention Center in Taiwan.
This year, ‘AMWC ASIA & TDAC (Aesthetic & Anti-aging Medicine World Congress & Taiwan Dermatology Aesthetic Conference)’ was visited by over 2,000 attendees.
At the conference, Hugel showcased its entire product lineup, including ▲the botulinum toxin ‘Letybo’, ▲the HA filler ‘Revolax’, and ▲cosmetics ‘Byryzn BR’ and ‘Wellage’.
After recording a market share of approximately 10% in its first year of launch in 2019, Hugel’s Taiwan subsidiary expanded its share to about 30% as of last year, currently maintaining the No. 2 position in the market.
Hugel CEO Jang Doo-hyun expressed his ambition, stating, “Through our participation in this event, we were able to reaffirm our network with local medical professionals in Taiwan and our brand competitiveness,” and “Based on a bundling strategy with our fillers and cosmetics, we will strengthen our product portfolio’s competitiveness and leap to the No. 1 position in the Taiwanese market.”
Choi Mun-hee
댓글
0